Pentadecapeptide BPC-157 has been studied in animals for more than three decades, and its human evidence base has stayed correspondingly thin. That is changing at the margin. In February 2026 a sponsor, Hudson Biotech, began recruiting for what is described as the first properly designed randomised controlled trial of BPC-157 in humans.
The trial
The study, registered as NCT07437547 and titled BPC-HAMSTR, is a randomised, double-blind, placebo-controlled Phase 2 trial in adults with an acute grade II hamstring muscle strain confirmed by MRI. It plans to enrol 120 participants, randomised to the investigational peptide or a matching placebo alongside a standardised rehabilitation programme. The two co-primary endpoints are time to return to unrestricted sport and change in MRI-assessed injury volume at day 14. Recruitment opened in February 2026 at a single centre, and primary completion is estimated for February 2027. No results have been posted.
Two features of the design matter for how the eventual result should be read. The endpoints are objective — time to return to sport and imaging-measured injury volume — rather than subjective symptom scores, which is unusual rigour for this area. And the trial is placebo-controlled and double-blind, which the existing human literature on BPC-157 is not.
What existed before
The human record for BPC-157 has rested on small, uncontrolled work. A retrospective chart review of sixteen patients given intra-articular BPC-157 for knee pain reported subjective improvement in fourteen, with no control group, no blinded assessment and no objective imaging endpoint. A separate small pilot study examined the safety of intravenous BPC-157 infusion in humans. A 2026 review in Sports Medicine of approved and unapproved peptide therapies for musculoskeletal injuries concluded that the lack of high-quality human clinical data remains the principal barrier to medical acceptance.
Against that, the preclinical column is deep. Reviews have catalogued more than 200 peer-reviewed animal studies across gastrointestinal, tendon, muscle and nerve models, with proposed mechanisms including angiogenesis, collagen synthesis and nitric oxide modulation. Preclinical findings of that kind establish biological plausibility. They do not establish clinical effect, and the recurring problem in this field is that the two are routinely conflated.
The UK regulatory position
BPC-157 holds no UK marketing authorisation and is not a licensed medicine in the UK. Where a product makes a medicinal claim, it falls under the Human Medicines Regulations 2012 and the MHRA's oversight. Registration in an overseas trial registry does not change the UK regulatory status of a research compound, and it is not a route to human use.
Peptide Data grades evidence by the human-data ceiling. On the current record, BPC-157 remains at the Limited grade: a deep preclinical literature and a nearly empty controlled-human one. The Phase 2 readout expected in 2027 is the event that could move that grade. It is stated here rather than implied that no controlled human efficacy data exist yet.
Peptide Data describes research findings and regulatory status only. Nothing here is consumption, dosing or self-administration guidance, and no outcome is claimed for any condition. Research use only.
This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.